More Challenges On The Road Ahead

- Figure 41

Bradley D. Chest 2016;00.

References

[1]

Malone S, Liu PP, Holloway R, et al. Obstructive sleep apnoea in patients with dilated cardiomyopathy: effects of continuous positive airway pressure. Lancet 1991;338:1480–1484.

[2]

Yumino D, Kasai T, Kimmerly D, et al. Differing effects of obstructive and central sleep apneas on stroke volume in patients with heart failure. Am J Respir Crit Care Med. 2013;187:433–438.

[3]

Kasai T, Yumino D, Redolfi S, et al. Overnight effects of obstructive sleep apnea and its treatment on stroke volume in patients with heart failure. Can J Cardiol. 2015;31:832–838.

[4]

Kaneko Y, Floras JS, Usui K, et al. Cardiovascular effects of continuous positive airway pressure in patients with heart failure and obstructive sleep apnea. N Engl J Med. 2003;348:1233–1241.

[5]

Usui K, Douglas Bradley TD, Spaak J et al Inhibition of awake sympathetic nerve activity of heart failure patients with obstructive sleep apnea by nocturnal continuous positive airway pressure. J Am Coll Cardiol. 2005;45:2008–2011.

[6]

Wang H, Parker JD, Newton GE, et al. Influence of obstructive sleep apnea on mortality in patients with heart failure. J Am Coll Cardiol. 2007;49:1625–1631.

[7]

Arzt M, Young T, Finn L, et al. Sleepiness and sleep in patients with both systolic heart failure and obstructive sleep apnea. Arch Intern Med. 2006;166:1716–1722.

[8]

Barbé F, Durán-Cantolla J, Sánchez-de-la-Torre M, et al, for the Spanish Sleep and Breathing Network. Effect of continuous positive airway pressure on the incidence of hypertension and cardiovascular events in non-sleepy patients with obstructive sleep apnea: a randomized controlled trial. JAMA. 2012;307:2161–2168.

[9]

Sin DD, Logan AG, Fitzgerald FS, et al. Effects of continuous positive airway pressure on cardiovascular outcomes in heart failure patients with and without Cheyne-Stokes respiration. Circulation. 2000;102:61−66.

[10]

Bradley TD, Logan AG, Kimoff RJ, et al; CANPAP Investigators. Continuous positive airway pressure for central sleep apnea and heart failure. N Engl J Med. 2005;353:2025–2033.

[11]

Arzt M, Floras JS, Logan AG, et al; CANPAP Investigators. Suppression of central sleep apnea by continuous positive airway pressure and transplant-free survival in heart failure: A post hoc analysis of the Canadian Continuous Positive Airway Pressure for Patients With Central Sleep Apnea and Heart Failure Trial (CANPAP). Circulation 2007;115:3173−3180.

[12]

Effect of Adaptive Servo Ventilation (ASV) on Survival and Hospital Admissions in Heart Failure (ADVENT-HF). ClinicalTrials.gov Identifier: NCT01128816. https://clinicaltrials.gov/show/NCT01128816

[13]

Cowie MR, Woehrle H, Wegscheider K, et al. Adaptive servo-ventilation for central sleep apnea in systolic heart failure. Supplementary appendix. N Engl J Med. 2015; http://www.nejm.org/doi/suppl/10.1056/NEJMoa1506459/suppl_file/nejmoa1506459_appendix.pdf

[14]

Cowie MR, Woehrle H, Wegscheider K, et al. Rationale and design of the SERVE-HF study: treatment of sleep-disordered breathing with predominant central sleep apnoea with adaptive servo-ventilation in patients with chronic heart failure. Eur J Heart Fail. 2013;15:937–943.

[15]

Cowie MR, Woehrle H, Wegscheider K, et al. Adaptive servo-ventilation for central sleep apnea in systolic heart failure. N Engl J Med. 2015;373:1095–1105.

[16]

Bradley TD, Floras JS. The SERVE-HF trial. Can Respir J. 2015;22:313.

[17]

ResMed Ltd. Important medical device warning: Increased risk of cardiovascular death with adaptive servo-ventilation (asv) therapy for patients with symptomatic chronic heart failure with reduced ejection fraction. May 13, 2015.